Development of Peptide-Drug Conjugates Targeting Glioblastoma Cells
ISEF · 2026 Chemistry
Overview
Glioblastoma accounts for 50.1 percent of all primary malignant brain tumors. Tumor stem cells play a key role in treatment resistance and tumor recurrence, as they are capable of self-renewal, have tumor-initiating capabilities, and are adaptable to environmental stress, including chemotherapy. The aim of this study was to generate variants of an already published peptide that specifically targets the Cadherin 2 membrane proteins and receptors found on glioblastoma stem cells, which may improve diagnostics and therapeutic targeting. I synthesized the peptides, using flow technology - a method that enables faster and more accurate solid-phase peptide synthesis, uses less material, produces less environmentally harmful "waste", making it more cost-effective and environmentally friendly. The most important result of the study so far is the structure-activity relationship of the peptide – daunomycin conjugates based on the CD spectroscopy analysis and MTT assays. It was shown that the AWEFWFP sequence-based derivative -when compared to the other peptides- has a slightly more ordered structure. In contrast, the others indicate very dynamic and mobile disordered structures without a characteristic structures but they also showed a partial bend structure or even the formation of a temporary beta sheet structure. The MTT test result obtained highlighted that the conjugate containing Tyr instead of Trp in position 2 (Dau=Aoa-LRRY-AYEFYFP-NH2) showed similar activity to the original targeting peptide with additional advantages: the conjugate is easier to synthesize due to the absence of tryptophan, and is less insoluble than other conjugates, thus these properties make it more suitable for further drug development.
Awards (2)
- Drug, Chemical & Associated Technologies Association (DCAT): DCAT First Prize
- American Chemical Society: Diploma of Recognition and $100 gift card $100
Competition history
- ISEF 2026
Resources
Related projects
CWSF · 2026
Brain-Penetrating Bioconjugate M13-CTX-PEP-1 for Targeted Glioblastoma Therapy In Silico
ISEF · 2024
Development of Pre-Clinical Assays for Quality Control of Cancer Imaging Agents
ISEF · 2024
Cancer Therapeutics — Harnessing Integrin Inhibition Property of Modified Naturally Secreted Peptide
ISEF · 2014
Treating GBM BTSCs through Growth Factor Stimulation and Drug-Polymer Conjugate Therapy
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair